111In-labeled anti-PSMA-FPI-2264 (Fusion Pharma)

N/A

Report date: 2025/06/11 11:25:14
NME

Base Information

Drug Name111In-labeled anti-PSMA-FPI-2264 (Fusion Pharma)
Drug Alias Nameindium111-FPI-2264 (Fusion Pharma)111In-labeled-FPI-2264 (Fusion Pharma)[111In]-FPI-2264FPI-2264FPI-2264-[In-111] +[7] 
ClassificationSmall moleculesRadiation-emitting products > Radioactive diagnostic agentDiagnostic agent (In vivo)
Mechanisms of ActionSPECT contrast agentProstate-Specific Membrane Antigen modulators
TargetsProstate-Specific Membrane Antigen
Therapy Area/IndicationsProstatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanada
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesFusion Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesFusion Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsProstatic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A